VivoSeq
Other

Elderly

0

Pipeline Programs↗

17

Active Trials↗

34

Companies Involved↗

Elderly is an early-stage landscape with 0 programs across 34 companies. The most active players are Wen-Ming Cao, Pfizer, Astellas.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

W

Wen-Ming Cao

1 program

ApprovedPfizer logo

Pfizer

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalEisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

177

clinical trials

Completed135 · 76%
Unknown status13 · 7%
Terminated11 · 6%
Recruiting9 · 5%
Not yet recruiting5 · 3%
Active, not recruiting3 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

177 trials

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07215585·420 enrolled
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Recruiting·FFirst Affiliated Hospital of Ningbo University·Phase 2·NCT06764017·30 enrolled
Venetoclax-Decitabine in Untreated Elderly/Unfit AML
Recruiting·TThe Second Hospital of Hebei Medical University·N/A·NCT07117422·39 enrolled
Radioembolization in Elderly/ Fragile Patients With mCRC
Recruiting·UUMC Utrecht·Phase 2·NCT05092880·220 enrolled
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Recruiting·NNYU Langone Health·Phase 3·NCT05799378·330 enrolled
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Recruiting·—·Phase 4·NCT06571825·118 enrolled
A Study on the Efficacy and Safety of Olaparib Combined With Trasotuzumab and Pertuzumab in Neoadjuvant Treatment for Elderly Patients With HER-2 Positive Breast Cancer
Recruiting·—·Approved·NCT07695259·45 enrolled
Smart Health Care and Innovative Technology Service Model Plan : Development of Innovative Health Promotion System for Senior Adults
Recruiting·NNational Cheng-Kung University Hospital·Preclinical·NCT04137939·400 enrolled
Evaluation d'un Prototype de Chambre Innovante adaptée au Grand Age
Recruiting·UUniversity Hospital, Angers·Preclinical·NCT06098534·200 enrolled
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05911321·6 enrolled
Bictegravir in the Elderly Living With HIV (BICEP)
Active, not recruiting·SState University of New York at Buffalo·N/A·NCT05064020·162 enrolled
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
Active, not recruiting·MMonash University·Phase 4·NCT05586750·341 enrolled
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Not yet recruiting·PPeking University People's Hospital·Phase 3·NCT07407660·250 enrolled
ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly
Not yet recruiting·TThe First People's Hospital of Lianyungang·N/A·NCT07096115·45 enrolled
Ultra-Short Regimen for Elderly DS-TB
Not yet recruiting·SShenzhen Third People's Hospital·Phase 3·NCT07076225·300 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)